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Abstract  
Although the role of immune dysregulation in hidradenitis suppurativa (HS) has yet to be 
elucidated, recent studies identified several complement level abnormalities in HS patients. The 
complement system serves a critical role in the modulation of immune response and regulation of 
cutaneous commensal bacteria. Complement is implicated in several inflammatory skin diseases 
including SLE, angioedema, pemphigus, bullous pemphigoid, and HS. A simplified model for 
HS pathogenesis is proposed, integrating the role of commensal bacteria, cutaneous immune 
responses, and complement dysregulation. The profound role of complement in disease 
pathogenesis has led to the development of novel anti-complement agents and clinical trials 




The complement pathway serves an important role in the innate immune response and defense 
against bacterial infection. Through the opsonization and lysis of pathogens, complement 
proteins facilitate the removal of immune complexes and damaged cells. Recently, there is a 
newfound appreciation for the role of complement in neuroinflammation, aging, and cancer 
(Hajishengallis et al., 2017, Hess and Kemper, 2016, Zhuang and Lyga, 2014). The complement 
system consists of approximately 50 soluble and membrane-associated proteins, including the 
classic constituents, C1-C9. While the majority of soluble factors are produced by the liver (Hess 
and Kemper, 2016), complement proteins are also secreted by a variety of cutaneous cells 
including mast cells, macrophages, keratinocytes, and fibroblasts (Zhuang and Lyga, 2014). 
Complement is traditionally considered part of the innate immune system, but its role in B and 
T-cell activation enhances adaptive immune response as well.  
The three core mechanisms of complement activation include the classical, lectin, and alternative 
pathways (Figure 1). Classical pathway activation occurs by antigen-antibody complexes, lectin 
pathway by bacterial polysaccharides, and alternative pathway by spontaneous activation at low-
levels for background immune surveillance. All three pathways converge to produce C3 
convertase, leading to the formation of C5 convertase and eventually the membrane attack 
complex (MAC). Through the “extrinsic” pathway, certain proteins directly cleave C5, including 
trypsin, thrombin, elastase, cathepsin D, granzyme B, and proteases produced by specific 
bacteria (Potempa and Potempa, 2012, Riedemann et al., 2017). Effectors include 
anaphylatoxins, C3a and C5a, to activate the immune system; and C3b to opsonize cells for 
phagocytosis. C3a and C5a bind to their respective receptors on a wide range of immune cells to 
propagate the inflammatory cascade (Frew et al., 2019a, Giang et al., 2018). C5b-9 may 
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assemble to form the MAC on cell membranes for bacterial lysis. Numerous regulators of this 
pathway exist to protect self-cells from lysis and overactivation of complement (Clarke and 
Tenner, 2014). 
There is renewed interest regarding the complement pathway as a pathogenic actor in chronic 
cutaneous inflammatory diseases. Dermatologists need a greater understanding of this complex 
pathway as potential imbalances may be of critical pathophysiologic significance in 
inflammatory skin diseases. This review provides an update regarding the role of complement in 
cutaneous health and disease, integrated into the current pathogenic paradigm for HS. The 
prospect of complement proteins as novel, rational therapeutic targets is also discussed, with the 
expectation of significant future developments in this area.  
Complement in Cutaneous Health and Disease 
Complement appears to play a vital role in the maintenance of cutaneous health. The use of C5a 
receptor antagonists in mice altered the composition and reduced the diversity of commensal 
skin flora (Chehoud et al., 2013). Additionally, C5a receptor (C5aR1) deficient mice presented 
with decreased expression of inflammatory genes and reduced number of infiltrating T-cells and 
macrophages. It was particularly noteworthy that C3 and C5aR1 deficient mice had accelerated 
wound healing response time (Rafail et al., 2015). In a murine model of cutaneous inflammation 
using imiquimod, a TLR7/8 antagonist, C3 was found to exacerbate inflammatory response 
(Giacomassi et al., 2017, Mihai et al., 2018). Overall, the levels and impact of complement 
anaphylatoxins appear to be correlated with the extent of inflammation in these murine models.  
Complement has been directly implicated in a number of human skin diseases, including HS, 
angioedema, SLE, pemphigus and bullous pemphigoid among others described in Table S1.  
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Coates et al recently reviewed the role of innate antimicrobial immunity in the skin (Coates et 
al., 2018). Complement evasion strategies have been developed by specific microbes (Panelius 
and Meri, 2015). Borrelia spirochetes bind soluble complement regulatory proteins to avoid 
attack. The capsule and thick peptidoglycan layer of Group A Streptococcus (Streptococcus 
pyogenes) decreases the efficacy of MAC and protects the bacteria from phagocytosis. 
Staphlococcus aureus secretes small proteins that interfere with C3 function to inhibit 
opsonization and anaphylatoxin production (Panelius and Meri, 2015). Herpes simplex virus type 
1 may also evade the effects of complement through a complement-interacting glycoprotein that 
can interfere with C1q, C3, C5, and properdin (Lubinski et al., 2002). Hence, the complement 
pathway serves an important role in the maintenance of skin health, pathogenesis of cutaneous 
disease, and in host-microbial interactions.  
Pathogenic pathways in Hidradenitis Suppurativa 
HS is a chronic skin disease characterized by recurrent painful nodules, abscesses, and 
suppurative dermal tunnels in intertriginous body regions. Recent epidemiologic data suggests 
HS may be relatively common, with an estimated prevalence of 1.19% (Ingram et al., 2018). 
Several updated guidelines for the management of HS have been recently published (Alikhan et 
al., 2019a, 2019b, Ingram et al., 2019).  
Although the specific pathogenic pathways and cytokine signatures of HS remain unclear, a 
proposed model is presented in Figure 2, incorporating recently published data from a systematic 
review of the literature (Hoffman et al., 2017, Vossen et al., 2018). As dilated follicular units in 
intertriginous areas in predisposed individuals rupture, hair follicle contents, including 
commensal microbiota and keratin may initiate innate immune response. Release of IL-1 from 
activated inflammasomes drives the production of pro-inflammatory cytokines, including TNF, 
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IL-6, and IFN-γ. These inflammatory mediators lead to dendritic cell activation, IL-23 
production and Th17 polarization. Keratinocyte response results in the increased production of 
TNF and antimicrobial peptides (AMPs). HS keratinocytes show a distinct pattern of AMP 
production in response to microbial products compared to control keratinocytes (Hotz et al., 
2016). Several AMPs have been measured in the serum of HS patients, such as S100A8 and 
S1000A9 (Wieland et al., 2013) and lipocalin (LCN2) (Wolk et al., 2017). Complement 
activation of inflammasomes directly may amplify these cutaneous inflammatory circuits 
(Arbore and Kemper, 2016). 
The role of sweat glands in this disease also remains unclear. Although the intertriginous areas 
are rich in apocrine glands (Hoffman et al., 2017, Vossen et al., 2018), eccrine gland 
transcriptomic signatures are also dysregulated in HS (Coates et al., 2018). Additional dermal 
factors, such as aberrant fibroblast responses, may contribute to the inflammatory sequelae of HS 
(Frew et al., 2019b), including dermal tunnels, persistent suppuration, fibrosis, and systemic 
inflammation. The development of biofilms on epithelialized tunnels may explain HS flares. 
Although skin and serum TNF levels from HS translational studies have shown inconsistent 
results (Frew et al., 2018), the anti-TNF agent, adalimumab (Humira, Abbvie), is currently the 
only FDA-approved biologic for HS. Ongoing clinical trials are investigating the efficacy of 
other immunomodulator anti-cytokine therapies, including anti-IL-1, anti-IL-17, (Theut Riis et 
al., 2018, Wlodarek et al., 2019), and anti-IL-23 (clinicaltrials.gov).  
Complement Pathway in Hidradenitis Suppurativa 
Kanni et al. recently reported elevated C5a and soluble C5b-9 in the serum of 54 HS patients 
compared to 14 healthy controls, although neither correlated with disease severity (Kanni et al., 
2018). A previous study conducted by this group found that the peripheral blood mononuclear 
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cells (PBMCs) of HS patients produced less cytokines in response to bacterial stimuli relative to 
controls (Kanni et al., 2015). However, part of the recent study enriched the PBMCs (n=7) with 
patient plasma and found that the plasma transformed PBMCs into overproducers of TNF-α; an 
effect that was attenuated by the C5a-antagonist, IFX-1. These findings suggest C5a may 
promote TNF-α production by monocytes.  
Analysis of skin and blood transcriptomes, and blood proteome data from HS patients discovered 
several complement factors that were dysregulated (Hoffman et al., 2018). In the skin 
transcriptome, there was upregulation of C1q, C2, and factor B, and downregulation of factor H, 
factor D, and C7. In the blood proteome, only C5a was upregulated, and C4b, C3, C3b, and iC3b 
were downregulated in HS (Hoffman et al., 2018). Gene Set Variation Analysis (GSVA) also 
found differential activation of the hallmark complement pathway in HS skin transcriptome, 
blood transcriptome, and blood proteome.  
Proposed Implications of Complement Dysregulation in Hidradenitis Suppurativa 
It remains unknown whether the complement dysregulation seen in HS reflects a primary change 
that drives pathogenesis or presents as an epiphenomena of later stage disease. Since the 
classical, alternative, and lectin pathways converge to produce C5 convertase and C5a was 
elevated in the serum, all three pathways may contribute to HS pathogenesis. The primary 
function of complement includes activation of the immune system via anaphylatoxins, 
opsonization, and bacterial lysis; all potential early and/or amplifying events in HS (Figure 2). 
Elevated C5a in HS suggests complement overactivation in these patients. Additionally, specific 
complement components may be reduced due to consumption. For example, decreased C3 may 
result from increased complement activity with C3b production for bacterial opsonization and 
C3/C5 convertase formation. Although the skin transcriptome had decreased C7 (Hoffman et al., 
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2018), and the serum had increased soluble C5b-9 (Kanni et al., 2018), the relationship between 
these findings remains unclear.  
Complement and TNF are interlinked inflammatory molecules in innate immune responses.  
Kanni et al suggested C5a may prime the production of TNF by human monocytes in HS (Kanni 
et al., 2018). Numerous examples of complement-dependent TNF release have been reported 
(Page et al., 2018), with C5a as a critical stimulator of TNF release (Liu et al., 2015). 
Additionally, TNFα may induce complement activation through the upregulation of C3 (Page et 
al., 2018), alternative pathway components, decreased production of surface regulatory proteins 
(CD141), and impaired Protein C activation (Sartain et al., 2016). Translational studies in 
rheumatoid arthritis and psoriasis demonstrated an an overall reduction of C3 and C4 with 
treatment using anti-TNF agents (adalimumab, infliximab, and etanercept) (Chimenti et al., 
2012, Di Muzio et al., 2011). The proposed bi-directional TNF-complement axis in the 
pathogenesis of HS is indicated in Figure 2. 
The role of microbiota in HS pathogenesis 
The dysregulated complement signature of HS in conjunction with the critical role of 
complement in host anti-microbial response warrants reconsideration of the potential role 
microbial species may play in HS pathogenesis (Belkaid and Segre, 2014, Naik et al., 2019). One 
explanation for the complement irregularities identified in HS involves the concept of dysbiosis, 
the alteration of normal commensal microbial composition in an organ (Park and Lee, 2017). The 
majority of bacteria present in HS are commensal microbes. With the use of modern molecular 
techniques, an abundance of Porphyromonas and Prevotella gram-negative anaerobic rods were 
identified in HS lesions (Guet-Revillet et al., 2014, Ring et al., 2019, Ring et al., 2017). Two 
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additional taxa of anaerobes, Fusobacterium and Parviomonas, correlated with clinical severity 
of HS (Guet-Revillet et al., 2014).  
Although HS does not fulfill Koch’s postulates of infectious disease, the dysbiosis of commensal 
bacteria may drive disease pathogenesis (Naik et al., 2019). Contextual pathogenicity depends on 
a series of host and microbial factors that may manifest as disease (Chen et al., 2018). Atopic 
dermatitis, inflammatory bowel disease, and sepsis are examples of this concept, (Biedermann 
and Rogler, 2015, Kobayashi et al., 2015, Maekawa et al., 2014, Singh et al., 2016, Yang et al., 
2018). A combination of factors may contribute to dysbiosis, including immune dysregulation, 
hormonal change, and microbiota imbalance.  
Proposed relationship between Genetics and Complement 
Mutations of ! -secretase, the trans-membrane protease complex that activates Notch, have been 
identified in some HS patients (Frew et al., 2017), and ! -secretase loss of function mutations 
may impair Notch signaling. However, the pathologic significance of these mutations and the 
close proximity of many identified mutations to the extracellular surface of ! -secretase remains 
unknown (Frew et al., 2017).  
CD46 is a transmembrane complement regulatory protein that can be cleaved by !-secretase 
(Yamamoto et al., 2013) and Porphyromonas gingivalis (Mahtout et al., 2009). This cofactor 
also mediates complement regulation through inhibition of C3b and C4b. As CD46 binds to the 
C3b attached to host cells, serine protease factor I cleaves C3b into its inactivated form, iC3b, 
preventing further amplification of the complement cascade. Polymorphisms of CD46 have been 
associated with atypical hemolytic uremic syndrome (aHUS), SLE, glomerulonephritis, systemic 
sclerosis, and other diseases of complement dysregulation (Liszewski and Atkinson, 2015). 
Furthermore, CD46 interaction with C3b induces intracellular T-cell polarization into Th1 cells, 
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while simultaneously upregulating IL-10 to increase the negative feedback regulation for Th1 
response (King et al., 2016).  
These findings suggest a potential link between !-secretase mutations in HS, commensal 
bacteria, and the serum complement dysregulation observed in HS. Genetic mutations in !-
secretase may impair CD46-mediated negative feedback, leading to unrestrained T-cell and 
complement activation that propagates inflammation in the pathogenesis of HS.  
Strategies for Anti-Complement Therapies  
Recent appreciation for the role of complement in disease pathogenesis has led to the 
development of novel targeted therapies (Figure 1).  
Eculizumab (Soliris, Alexion Pharmaceuticals) is a monoclonal antibody that binds to C5 and 
inhibits its cleavage by C5-convertase into C5a and C5b. This FDA-approved anti-C5 agent is 
indicated for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic 
syndrome (aHUS) (Morgan and Harris, 2015). In PNH, affected red blood cells (RBCs) lack two 
glycolipid-anchored complement inhibitory proteins (CD55 and CD59). This deficiency 
predisposes them to persistent C3 opsonization and MAC-mediated intravascular hemolysis. 
Two large multicenter trials confirmed the efficacy of eculizumab for PNH with improved 
clinical response (reduced transfusion needs, hemoglobin stabilization, resolution of hemolysis-
related symptoms) (Mastellos et al., 2018). In aHUS, genetic complement regulatory 
abnormalities and anti-complement antibodies result in continuous spontaneous hydrolysis of C3 
and activation of the complement cascade. Unrestrained complement leads to microangiopathic 
hemolytic anemia, thrombocytopenia, and renal failure. Eculizumab inhibits complement-
mediated thrombotic microangiopathy and improves renal outcomes for aHUS patients 
(Legendre et al., 2013, Noris et al., 2014).  
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Ravulizumab (ravulizumab-cwvz, Ultormiris, Alexion Pharmaceuticals), a long acting form of 
the first-generation C5-inhibitor, eculizumab, received FDA-approval for PNH in 2018 
(McKeage, 2019). Ravulizumab was noninferior to eculizumab for the treatment of PNH in 
patients that were complement-inhibitor naïve (Lee et al., 2019) and patients previously treated 
with eculizumab (Kulasekararaj et al., 2019). The 8-week maintenance frequency of ravulizumab 
provides a more favorable dosing schedule than the 2-week maintenance frequency of 
eculizumab. Given the prolonged half-life of ravulizumab, patients may also experience fewer 
episodes of breakthrough hemolysis (Connell, 2019).  
IFX-1 (InflaRx, GmBH) is a monoclonal anti-C5a antibody (Maarouf et al., 2018). In a small 
proof of concept study, HS patients with advanced disease at a single European site received a 
weekly infusion of IFX-1. This therapy resulted in 75% of patients meeting the primary clinical 
endpoint (HiSCR) at 12-weeks, and 83% at the end of the 12-week follow-up period. This 
biological agent is now in clinical trials for HS in the United States and Canada (NCT 
03487276).  
BIVV009 (Sutimulimab, originally known as TNT003, Bioverativ) is an antibody against C1s. 
This approach targets the classical complement pathway, theoretically leaving the alternative and 
lectin pathways intact. BIV009 has been granted orphan drug status by the FDA in 2017 and is 
now in clinical trials for bullous pemphigoid (Kushner and Payne, 2018).  
PMX-53 (Peptech), a potent C5a-receptor antagonist that results in a dose-dependent inhibition 
of C5a-mediated activation, had limited success in phase II clinical trials for osteoarthritis, 
rheumatoid arthritis and psoriasis (Morgan and Harris, 2015). The short half-life and rapid break-
down of this compound may explain the reported inefficacy of this treatment (Holers and Banda, 
2018). PMX205, a lipophilic analogue of PMX-53 with improved in vivo stability and 
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efficacy has been suggested as a better drug candidate, particularly for neurological conditions 
due to increased blood brain barrier permeability (Kumar et al., 2018). 
CCX168 (Avacopan, ChemoCentryx) is an orally administered, small molecule selective C5aR 
inhibitor; it has shown safety and efficacy in a phase II, randomized, placebo-controlled trial 
(CLEAR) in patients with ANCA-Associated Vasculitis. The primary efficacy measure of 
greater than 50% reduction in Birmingham Vasculitis Activity Score by week 12 with no 
worsening of any organ system was achieved in 86.4% (p=.002 for noninferiority) of patients 
treated with avacopan plus 20 mg prednisone and 81.0% (p=.01 for noninferiority) of patients 
solely treated with avacopan, compared to 70.0% in the control group treated with 60 mg 
prednisone. These findings support avacopan as an effective substitute in replacing high-dose 
glucocorticoids in treating vasculitis (Jayne et al., 2017, Tan and Zhao, 2018). A phase II study 
was recently initiated for avacopan in HS (NCT03852472).  
The major risk factor associated with inhibition of the terminal complement pathway is Neisseria 
meningitidis infection, over a thousand-fold more frequent in patients with terminal complement 
deficiencies (Barnum, 2017, Lewis and Ram, 2014). Vaccination is highly recommended prior to 
commencing treatment targeting the C5 pathway. However, the risk of Neisseria meningitidis 
infection in patients with genetic complement deficiencies is greater than the risk observed in 
patients with PNH treated with eculizumab, although this difference may be attributed to greater 
immunization rates and prophylactic antibiotics in the latter. IFX-1 inactivates circulating C5a 
and may have a better safety profile than agents inhibiting the C5 convertase. Due to the 
association of early classical pathway component deficiencies (C1q and C4) with lupus-like 
symptoms, potential treatments targeting these components should be further evaluated. 
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Conclusion  
The complement pathway serves an essential role in immune regulation that may be implicated 
in the pathogenesis of several inflammatory skin diseases including HS, vasculitis, SLE, and 
bullous pemphigoid. Several ongoing clinical trials of molecules targeting C5 and C1 will 
evaluate their potential role in the treatment of HS in the near future. Promising results were 
obtained from a single center, proof of concept trial using a monoclonal anti-C5a antibody for 
HS, but larger clinical trials are urgently required to demonstrate the role of complement in the 
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Role of the Complement Pathway in Inflammatory Skin diseases: A focus on hidradenitis 
suppurativa (HS) 
Mondana H. Ghias, Michael J. Hyde, Lewis Tomalin, B. Paul Morgan, Afsaneh Alavi, Michelle 
A. Lowes, Vincent Piguet. 
 
Table S1. Complement in cutaneous diseases	
Disease Proposed role of complement in pathogenesis 
Hereditary and acquired 
angioedema 
C1-inhibitor (C1-INH) deficiency (genetic mutation or 
acquired autoantibodies) cause overactivated complement and 
excess bradykinin levels. Bradykinin leads to increased 
vascular permeability and angioedema (Csuka et al., 2017, 
Zeerleder and Levi, 2016) 
Systemic lupus 
erythematosus 
Autoantibodies directed against DNA and histones may 
induce uncontrolled complement activation, leading to 
secondary complement consumption and organ damage; 
impaired clearance of immune complexes and apoptotic debris 
may trigger increased autoimmune response (Leffler et al., 
2014, Zharkova et al., 2017)  
Vasculitis Perivascular C3d deposits and MAC; C3a and C5a increase 
endothelial cytokine release and vascular leakage; C5a 
translocates ANCA to cell surface and stimulates neutrophils 
leading to endothelial injury and coagulation pathway 
activation (Chen et al., 2017) 
Pemphigus  C1q, C3, C4, and properdin found in intercellular substance; 
autoantibody activation of complement causes loss of 
intraepidermal keratinocyte cohesion and blister formation 
(Panelius and Meri, 2015) 
Bullous pemphigoid Autoantibodies fix complement to basement membrane, 
increasing inflammation and blister formation (Hammers and 
Stanley, 2016); C5a-C5aR1 axis is critical for disease 
pathogenesis in autoimmune blistering murine-model; anti-C5 
treatment ameliorates disease (Mihai et al., 2018)  
Partial lipodystrophy Associated with abnormal complement activator, C3 nephritic 
factor, stimulating C3 convertase and C3b deposition; 
alternative pathway and MAC damage adipose cells (Panelius 
and Meri, 2015) 
	 2	
Primary and functional 
complement deficiency-
related skin infections 
Pyogenic skin infection associated with lack of C2 and factor 
I deficiency; factor I inactivates C3b/C4b and decreased factor 
I leads to secondary C3/factor B deficiency (Panelius and 
Meri, 2015); deficiency of properdin or terminal complement 
components (C5b-C9) increases risk of invasive Neisserial 
infections (Bathum et al., 2006, Schneider et al., 2007)  
Hidradenitis suppurativa Elevated C5a and soluble C5b-9 in the serum of HS patients 
(Kanni et al., 2018); in the skin transcriptome, C1q, C2, and 
factor B genes were upregulated, while factor H, factor D, and 
C7 were downregulated. In the serum proteome, C5a was 
upregulated, and C4b, C3, C3b, and iC3b were downregulated 
(Hoffman et al., 2018) 
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Figure	1.	Complement	pathways	and	inhibitors.	Classical,	lectin,	alterative	pathways	converge	to	produce	C3	
convertase	(C4b2a	and	C3bBb),	which	then	produces	C5	convertase	(C4b2a3b	and	C3bBb3b).	Various	enzymes	and	
bacteria	can	directly	cleave	C5	via	the	“extrinsic”	pathway.	Inhibitors	of	complement	effectors	that	are	currently	in	
development	are	shown	in	red.		
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Figure	2.	Proposed	simplified	role	of	the	complement	pathway	in	hidradenitis	suppurativa	(HS)	pathogenesis.	
Initiating	factors	are	strong	inducers	of	innate	immune	responses	(IR)	in	patients	with	a	predisposition	for	HS.	
Cutaneous	immune	responses	(blue	box)	lead	to	keratinocyte	(KC)	activation	with	abundant	cytokine	and	antimicrobial	
peptide	(AMP)	production.	Complement	has	known	pro-inflammatory	and	anti-bacterial	effects	and	relationships	
(dotted	orange	box)	although	they	have	not	yet	been	proven	in	HS.	Targeted	anti-cytokine	biologics	are	shown	in	red.	
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